Literature DB >> 11690557

Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells.

H Miyake1, S Hara, T Zellweger, S Kamidono, M E Gleave, I Hara.   

Abstract

Recent studies have shown the antiapoptotic activity of clusterin against a wide variety of stimuli; however, the functional role of clusterin in Fas-mediated apoptosis has not been well characterized. We transfected the clusterin cDNA into human renal-cell carcinoma (RCC) ACHN cells that scarcely express clusterin protein in order to examine whether overexpression of clusterin inhibits the Fas-mediated signal pathway for apoptotic cell death. No significant difference was observed in the in vitro cell growth rates between the clusterin-transfected cell line (ACHN/CL) and the vector-only-transfected control cell line (ACHN/C), whereas the colony-forming efficiency in soft agar of ACHN/CL was significantly higher than that of ACHAN/C. The anti-Fas monoclonal antibody CH11 induced apoptosis in ACHAN/C cells in a dose-dependent manner; however, the growth-inhibitory effect of CH11 on ACHN/CL cells was markedly suppressed, with corresponding increases in p53 expression and decrease in the fraction of cells in the sub-G(1) phase of the cell cycle. Furthermore, the cytotoxic effect of CH11 on ACHN/CL cells was augmented by treatment with interferon-gamma, but a corresponding effect on ACHN/C cells was not observed. These findings suggest that overexpression of clusterin may contribute to a phenotype resistant to Fas-mediated apoptosis, and that if interferon-gamma treatment is added according to the clusterin expression level, Fas-mediated therapy could be a novel approach to RCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11690557     DOI: 10.1089/10915360152559585

Source DB:  PubMed          Journal:  Mol Urol        ISSN: 1091-5362


  9 in total

1.  Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.

Authors:  Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

Review 2.  Clusterin and chemoresistance.

Authors:  Julie Y Djeu; Sheng Wei
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

Review 3.  Classical pathology versus molecular pathology in renal cell carcinoma.

Authors:  Peggy Soung Sullivan; JianYu Rao; Liang Cheng; Richard J Cote
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

Review 4.  Hepatitis D and hepatocellular carcinoma.

Authors:  Zaigham Abbas; Minaam Abbas; Sarim Abbas; Lubna Shazi
Journal:  World J Hepatol       Date:  2015-04-18

5.  Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.

Authors:  Brent Blumenstein; Fred Saad; Sebastien Hotte; Kim N Chi; Bernhard Eigl; Martin Gleave; Cindy Jacobs
Journal:  Cancer Med       Date:  2013-05-28       Impact factor: 4.452

Review 6.  Clusterin: a key player in cancer chemoresistance and its inhibition.

Authors:  Tomas Koltai
Journal:  Onco Targets Ther       Date:  2014-03-20       Impact factor: 4.147

7.  Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.

Authors:  Francois Lamoureux; Marc Baud'huin; Benjamin Ory; Romain Guiho; Amina Zoubeidi; Martin Gleave; Dominique Heymann; Françoise Rédini
Journal:  Oncotarget       Date:  2014-09-15

8.  HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells.

Authors:  Junmin Zhou; Xianghong Chen; Danielle L Gilvary; Melba M Tejera; Erika A Eksioglu; Sheng Wei; Julie Y Djeu
Journal:  Sci Rep       Date:  2015-10-15       Impact factor: 4.379

9.  Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.

Authors:  Y Kususda; H Miyake; M E Gleave; M Fujisawa
Journal:  Br J Cancer       Date:  2012-05-15       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.